Work

First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

Year: 2015
Type: article
Abstract: Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.
Source: PubMed
Author: Jack McCain
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: green
OpenAlex ID: W1861116198
FWCI: 1.297
Cites: 19
Cited by: 42
Related to: 10